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a  b  s  t  r  a  c  t
Neurodegenerative  diseases  get a growing  relevance  for societies.  But  yet  the complex  multi-factorial
mechanisms  of these  diseases  are  not  fully  understood,  although  it is  well  accepted  that  metal  ions  may
play a crucial  role.  Manganese  (Mn)  is  a transition  metal  which  has essential  biochemical  functions  but
from  occupational  exposure  scenarios  it appeared  that  Mn  can cause  severe  neurological  damage.  This
“two-faces”-nature  of manganese  initiated  us to  start  a project  on Mn-speciation,  since  different  element
species  are  known  to exhibit  different  impacts  on  health.  A summary  about  the  step-wise  developments
and  ﬁndings  from  our working  group  was presented  during  the  annual  conference  of  the  German  trace
element  society  in  2015.
This  paper  summarizes  now  the  contribution  to this  conference.  It is  intended  to provide  a  complete
picture  of  the so  far  evolved  puzzle  from  our studies  regarding  manganese,  manganese  speciation  and
metabolomics  as  well  as  Mn-related  mechanisms  of  neural  damage.  Doing  so,  the  results  of  the  single
studies  are  now  summarized  in  a connected  way  and  thus  their interrelationships  are demonstrated.  In
short  terms,  we  found  that  Mn-exposure  leads  to an  increase  of  low  molecular  weight  Mn  compounds,
above  all  Mn-citrate  complex,  which  gets  even  enriched  across  neural  barriers  (NB).  At a Mn  serum
concentration  between  1.5  and  1.9  g/L  a carrier  switch  from  Mn-transferrin  to  Mn-citrate  was  observed.
We  concluded  that the  Mn-citrate  complex  is that  important  Mn-carrier  to  NB  which  can  be found  also
beyond  NB  in  human  cerebrospinal  ﬂuid  (CSF)  or brain  of  exposed  rats.  In brain  of Mn-exposed  rats
manganese  leads  to  a  decreased  iron  (Fe)  concentration,  to  a shift  from  Fe(III)  to  Fe(II)  after  long  term
exposure  and  thus  to a  shift  toward  oxidative  stress.  This  was additionally  supported  by an  increase
of  markers  for  oxidative  stress,  inﬂammation  or lipid  peroxidation  at increased  Mn  concentration  in
brain extracts.  Furthermore,  glutamate  and acetylcholineesterase  were  elevated  and  many  metabolite
concentrations  were  signiﬁcantly  changed.
©  2016  The  Author.  Published  by  Elsevier  GmbH.  This  is  an open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/4.0/).
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. Introduction—background of the Mn  speciation project
Today, neurodegenerative diseases like Alzheimer’s disease
AD) and Parkinson’s disease (PD) are gaining increasing rele-
ance in our aging society. However, the complex multi-factorial
echanisms of these diseases are yet not sufﬁciently understood
1–3]. Metal ions, speciﬁcally chronic or excessive Manganese (Mn)
xposure is a cause of severe neurological dysfunction although
n is an element of janiform nature: It is an essential micronu-
rient required for normal physiological processes in mammals.
articularly, it plays important roles as a cofactor for a series
f enzymes including Mn-dependent superoxide dismutase [2],
hich are crucial for antioxidant defence, energy metabolism,
mmune function, reproduction, brain function, or DNA repair
4–6]. However, already since 1837 toxic neurological health effects
f Mn  are known. The most severe one is called manganism and was
rst described by James Couper in 1837. He observed paraplegia
n the lower extremities of Scottish MnO2-ore grinding workers
7]. Since then it has been explored that elevated levels of Mn
ay  cause damage of the central nervous system with symptoms
uch as adynamia/fatigability, sialorrhea, cephalalgia, sleep distur-
ances, muscular pain and hypertonia, masklike face, gait changes,
educed coordination, hallucinations, and mental irritability [8].
hese detrimental health effects are presumably induced by oxida-
ive stress, with inhalation being the primary route of concern for
ccupational health effects. Several of the above mentioned health
ffects are similar to symptoms of Parkinsonism (PD).
Exposure scenarios from occupational health are known for
iners, industrial steel workers or welders. Symptoms of man-
anism were found for some of the exposed individuals, but even
ore alarming, for the whole group an increased prevalence for PD
as reported. First concern about additional manifestation of Mn
eurotoxicity other than manganism was raised by a study from
acette et al. [9], reporting that in 953 cases the age at PD diagnosis
as 17 years earlier in career welders than in non-welders. Nowa-
ays, Mn  neurotoxicity is becoming of great public health concern
ue to diverse factors affecting even a broader range of population
10].
For example it is reported that population living in the
urroundings of big industrial vicinities or living close to highly-
requented trafﬁc routes with Mn  containing car exhaust from
ethylcyclopentadienyl-manganese-tricarbonyle (MMT)  charged
uel probably is at risk [11,12]. The group around Lucchini had
xtensively studied the population and PD prevalence around
he big ferroalloy plant in the province of Brescia, Italy, which
ere operating until 2001 [13]. Their results showed that an
nvironmental exposure to Mn  was associated with an increased
revalence of PD disturbances. Such chronic exposures may  pro-
ressively extend the site of Mn  deposition and toxicity from the .  . . . .  . . . . . .  . . . .  .  .  . .  .  . . . . . . .  . . . . . . .  .  . . . .  . . .  .  . . .  .  .  . . .  . . .  .  . . .  . . . .  . . .  . . .  . .  . .  . .  .  .  60
globus pallidus to the entire area of the basal ganglia, including the
substantia nigra pars compacta, involved in PD [14].
Based on these recent epidemiologic studies, Lucchini et al.
developed the concept of lifetime Mn  exposure with the hypothe-
sis of an increased risk of Parkinsonian disturbances, where lifetime
exposure to low Mn  levels, starting from prenatal to older age, may
be a risk factor for Parkinsonism.
Another epidemiological study investigated associations
between PD and exposure to industrial emissions of Mn  as well
as vehicle exhaust due to the use of MMT  added to gasoline since
1976 [11]. From these ﬁndings Finkelstein et al. [11] concluded that
ambient Mn  exposure lowers the age of PD diagnosis, suggesting
that Mn  exposure ampliﬁes the natural loss of neurons caused
by aging process. Overall, Finkelstein et al. [11] conclusions were
in line with Lucchiniı´s hypothesis [14] of an increased risk of
Parkinsonian disturbances after lifetime Mn exposure.
The janiform nature of manganese—its’ essential or potentially
detrimental role—prompted us to investigate Mn  speciation in
human serum, CSF and rat brain extracts after exposure, since
different Mn  compounds might be metabolized or transported
by different pathways, and by that way causing opposing health
effects.
The absorption of inhaled Mn  is high and it is well accepted that
Mn is transported to the liver, where it is metabolized and the newly
formed Mn species get transported with blood to brain. In literature
transferrin (Tf) was supposed to be a plasma Mn-carrier for physio-
logical condition, and a well-controlled transferrin-receptor (Tf-R)
mediated Mn  transport across the NB is known. However, under
Mn exposure, different Mn  species seem to cross the NB indepen-
dently from Tf-R. These different Mn  compounds appear in CSF. The
ﬁrst question in our project therefore related to Mn-speciation at
NB, because these Mn-compounds are key-metabolites which had
to be addressed according to differences in transport of Mn  to the
brain under varying conditions [15].
The second question relates to the neurotoxic mechanism of
Mn on the cellular level, which is still unclear. Common explana-
tions comprise reactive oxygen species (ROS) generation: Reasons
for ROS production were discussed regarding the various oxida-
tion states of Mn,  or its afﬁnity to mitochondria connected to
energy supply depletion in neurons, or by disturbance of cellu-
lar iron and calcium homeostasis [16]. But also Mn-related DNA
damage in neurons may  cause neurodegenerative effects, since
Mn(II) has been reported to substantially decrease the ﬁdelity of
DNA replication and it has been shown that in intact human cells
Mn(II) reduces the extent of poly(ADP-ribosyl) ation stimulated
by H2O2 at low, non-cytotoxic concentrations. It is important to
know that poly(ADP-ribosyl) ation is considered as a DNA-repair
system which occurs as one of the ﬁrst nuclear events shortly after
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NA strand break induction and is mediated by members of the
Poly(ADP-ribose) polymerase (PARP)-family” [17].
. The Mn-speciation project
.1. The concept
According to the above mentioned questions our scientiﬁc aims
ere 1.) to identify the mechanisms of less controlled and increased
n-transport into brain (Mn-carrier species) and 2.) to clarify the
echanism of neuronal damage by Mn.
The concept was realized by employing element speciation for
dentiﬁcation of the changed Mn-species in relevant human body
uids before (serum) and behind (cerebrospinal ﬂuid) NB.
Consequently the strategy for our studies was focused on
.1.1. Mn  transport into brain by
a) Mn-speciation in serum (before NB) and in CSF (behind NB),
b) investigating the permeability of the NB for e.g., Mn  apply-
ng element speciation in paired serum and CSF samples to reveal
isturbed metal species homeostasis,
c) evaluating the results from human samples by comparing to
peciation results of animal experiments after well-deﬁned Mn-
xposure.
.1.2. Clariﬁcation of the mechanism of neuronal damage by Mn
nd cellular defence by investigating the molecular mechanism
ehind Mn-induced neurotoxicity on the cellular level,
a) after low-dose singe i.v. injection, or
b) after low-dose 7 weeks feeding.
.2. The methodical approach
Classical speciation methods were used, comprising of hyphen-
tions of chromatography with element selective detectors, mainly
nductively coupled plasma mass spectrometry (ICP-MS) for Mn
nd Fe speciation, but also inductively coupled plasma optical
mission spectrometry (ICP-OES) for Fe(II)/(III) speciation. For
ifferentiation of Fe(II) from Fe (III) a hyphenation of IC with
CP-OES was employed. This combination of methods was  useful
ith regard to non-interfered element lines, short analysis time
∼5 min), applicability in biological samples, low sample amount
∼25 l) as well as good LoDı´s (Fe(II): 9.1 g/l, Fe(II): 6.3 g/l) and
olumn recoveries (Fe(II): 83–105%, Fe(III): 43–66%).
Element determinations were checked by analyisis of refer-
nce materials and participation in GEQUAS quality control system.
erial and day-to-day precision were 2.5% or 2.8%, accuracy was
etermined at 100.7%. Mn-speciation results comprised of samples
hich had been analyzed twice, with storage between ﬁrst and sec-
nd measurement. Uncertainties of Mn-speciation measurement
hus referred to storage stability and measurement variance of the
yphenated system. For Mn-species concentrations below 300 ng/L
n average RSD 18 ± 4% was found, whereas for Mn-species higher
han 300 ng/L an average RSD 7 ± 3% was seen.
Size exclusion chromatography (SEC) coupled to ICP-mass spec-
rometry with dynamic reaction technology (ICP-DRC-MS) and—for
lear identiﬁcation—capillary zone electrophoresis (CZE)-ICP-DRC-
S  were used in a 2D approach for speciation of Mn.  SEC offers
eparation of even labile metal species together with size char-
cterizations of compounds, however, it suffers from sufﬁcient
esolution and baseline separation. As a consequence doubtless
eak identiﬁcation is impossible. Therefore, ion exchange (IEC) and
eversed phase chromatography (RPC) were tested. However, these
ethods hampered Mn-species stability. When using RPC, stan-
ards like Mn-citrate showed only one peak co-eluting with the
norganic Mn  standard, indicating a separation of Mn from theedicine and Biology 37 (2016) 50–61
citrate-standard complex. Other standards appeared as multiple
peaks for only one compound and additionally sample sticking was
observed. IEC resulted in irreproducible Mn-chromatograms. These
limitations redirecting the experiments back to SEC combined with
CZE for a 2D identiﬁcation approach. Capillary electrophoresis
(CE) is one of the most powerful separation techniques. It pro-
vides very efﬁcient species separation, typically without altering
species stability. This is because no stationary phase with active
sites and high surface is involved in separation. Furthermore, CE
offers different modes of separation, such as capillary zone elec-
trophoresis (CZE), micellar electrokinetic chromatography (MEKC),
isoelectric focusing (IEF), isotachophoresis (ITP), and capillary elec-
trochromatography (CEC). This is important for multidimensional
strategies. For additional species veriﬁcation SEC fractions from
serum and CSF were subject also to electrospray ionization—Fourier
transform ion cyclotron resonance—mass spectrometry (ESI-FT-
ICR-MS) [18], a molecular mass spectrometric technique with
ultra-high resolution.
Fig. 1 summarizes the applied techniques for metal speciation
and non-targeted metabolomics investigations.
3. Manganese-speciation studies
3.1. Manganese-speciation in human samples
Investigations started with species characterization in human
serum and CSF. Pooled serum samples from the Munich region
showed mean Mn  concentration of 1.7 ± 0.8 g L−1. Mn  was  pre-
dominantly associated with the transferrin/albumin fraction and
to lesser amounts to the -2-macroglobulin fraction, each of these
carriers known as physiological ligands. However, an additionally
Mn peak was monitored at Mn-citrate standard retention time
which was  higher in those sera having slightly elevated total Mn
concentration up to 2.3 g/L [19]. This ﬁnding was discussed as a
ﬁrst indication that excess Mn  might be transported in blood by a
low molecular mass (LMM)  carrier like Mn-citrate.
Fifteen pooled CSF samples showed Mn  concentrations in the
range 1.8–6.7 g L−1 (mean 2.66 g L−1, ↔ mean 48 nM). Other than
in serum, 90% of Mn  in CSF was  bound to LMM  Mn  carriers. The
major fraction co-eluted with the Mn-citrate standard. We  con-
ﬁrmed this also by standard addition of Mn-citrate standard to
CSF (refer to Fig. 1 in Ref. [20]). Therefore, citrate was additionally
determined in CSF using enzymatic reaction with UV spectrophoto-
metric detection [19]. The mean concentration was  573 M (range
420–713 M),  proving citrate in huge excess compared to Mn  (ratio
Mn (meanvalue): citrate (meanvalue) = 1:12000). This surplus of citrate
made a Mn-citrate complex (aside from other metal citrate com-
plexes) in CSF likely. Fig. 2 shows a typical chromatogram of CSF
(Mn  and UV trace) and Mn-HSA or citrate standards for comparison.
For clear identiﬁcation of Mn-species capillary electrophore-
sis (CE) was  used to analyze CSF samples and SEC fractions from
serum and CSF, here as a second device for a 2D approach. Com-
pounds being supposed in literature to act as potential Mn  carriers
were analyzed. The respective standard mixture comprised of albu-
min, histidine, tyrosine, cystine, fumarate, malate, inorganic Mn,
oxal-acetate, a-keto-glutarate, nicotinamide-dinucleotide (NAD),
citrate, adenosin, glutathione, and glutamine. At the end, 13 Mn-
species were monitored in pooled CSF samples, most of them being
identiﬁed: Mn-histidine, Mn-fumarate, Mn-malate, inorganic Mn,
Mn-oxal-acetate, Mn--keto-glutarate, Mn  carrying NAD, Mn-
citrate and Mn-adenosin. By far the most abundant Mn-species was
Mn-citrate showing a concentration of 0.7 ± 0.13 g Mn  L−1. Inter-
estingly, most other Mn-species can be related to the citric acid
cycle, too.




























aig. 1. Schematic overview about the used methods in the Mn-speciation project. M
wo  2D approaches SEC/CE-ICP-DRC-MS or SEC/ESI-FT-ICR-MS. Fe(II and Fe(III) we
SI-FT-ICR-MS measurements.
The above ﬁndings motivated our group to investigate Mn-
pecies on an individual basis, with serum and CSF samples
orresponding to the same individual and time of sampling. Such
amples are considered as “paired samples” and allow Mn  specia-
ion before (serum/plasma) and behind (CSF) the NB: Consequently,
ischwitz et al. [21] investigated the permeability of the human
lood-CSF-barrier for selected metals including Mn.  Manganese
eak fractions in serum and CSF were quantiﬁed and ratios of
SF vs. serum were calculated. The main results of this study
ere signiﬁcant differences in the molecular size distribution of
he species of investigated metals for CSF and serum samples.
upposedly these differences were due to selective permeation
f metal species from serum across the NB. With respect to Mn
early all species were lower concentrated in CSF than in serum
xcept the Mn-citrate fraction, which was signiﬁcantly enriched
y a factor of 5. This was consistent with other ﬁndings from serum
nd cerebrospinal ﬂuid. The summarized key-messages of the
bove studies were the low amounts of LMM  Mn-species and the
igher amounts of high molecular mass (HMM) Mn-compounds in
uman serum, the latter being assigned to -2-macroglobulin and
ransferrin/albumin [21–23]. Contrary, in CSF only little amounts
f Mn-HMM-compounds were detected but predominantly LMM
n-species, with Mn-citrate above others being even ﬁve-foldnriched, were identiﬁed [21].
The importance of Mn-citrate is supported from others, too:
okel [8] found Mn-citrate present in plasma and suggested it
s a candidate for uptake into brain since the Kin for Mn-citrateeciation was performed by SEC-ICP-DRC-MS and for clear species identiﬁcation by
lyzed by IC-ICP-OES whereas metabolomics studies used methanolic extracts and
exceeded the calculated K-value for simple diffusion in six brain
regions, including the caudate [24]. The caudate, being part of the
basal ganglia, is involved in manganism and a site of Mn  accumula-
tion after exposure. With such a high uptake rate, Mn-citrate brain
inﬂux compares to the Mn2+ ion inﬂux.
In a follow-up study using paired samples, we investigated cor-
relations between Mn-citrate or other Mn-species and total Mn
concentration in paired samples of human serum and CSF. The Mn-
species concentrations from the different sample types (serum vs.
CSF) were interrelated and correlation coefﬁcients were calculated.
In a ﬁrst pilot study from 2013 [18], a limited sample size from
Munich was  investigated (n = 24) employing two 2-D approaches
based on SEC/CE-ICP-DRC-MS and SEC/ESI- FT ICR−MS technology.
In this pilot study the relevant [Mn(C6H5O7)2]4− complex was
detected as the predominant Mn-citrate species existing around
neutral pH in a native sample. The concentrations ranged from ca.
0.2–0.55 g/L for the citrate complex, related to Mn, determined
in CSF samples at total Mn  concentrations of 0.21–1 g/L. This was
an improvement compared to our former report with a limit of
detection for Mn-citrate of 250 g Mn/L [25], which however was
produced with an old ESI–MS/MS instrument.
The evaluation of speciation results revealed that Mn-species
concentrations correlated differently to total Mn  concentration
dividing the samples into two  groups:
Below serum Mn  (total) concentration ≤1.55 g/L the Mn-
transferrin/albumin fraction was positively correlated with total
Mn in serum and with total Mn  in CSF, whilst above a Mn total

































big. 2. Size screening of Mn species in a CSF sample using a mass calibrated TSK-4
tandard. The Mn-albumin trace indicated the void volume where no Mn from CSF 
oncentration of ca. 1.9 g/L, the total Mn  concentrations of serum
nd CSF were positively correlated with Mn-citrate in serum. For
ncreasing the statistical power of these results a follow-up study
ith a sample size of 141 serum and 39 serum/CSF sample pairs
total 180 serum samples) were used and additionally regional dif-
erences were explored. The whole sample set in this second study
onsisted of three subsets from Munich, Emilia Romagna region in
taly and from Sweden.
Total manganese serum concentrations were similar for the
unich and Swedish samples but differed for the Italian subset. The
ajority of Swedish samples were in the range of 0.4–1.5 g/L total
n,  the Munich samples ranged mainly from 0.5–1.9 g/L, while
talian samples tended to be higher in the range of 0.9–ca. 4 g/L.
rom all subsets some samples reached even higher values. These
oncentration ranges are in line with literature data. Total man-
anese serum concentrations are reported e.g., from USA on a daily,
eekly and monthly basis to be stable between 0.84–0.98 g/L
26]. Versiek et al. report a range from 0.4–1.05 g/L for Belgium
27]. Heitland reports for whole blood a range of 4–18 g/L with a
ean at 9 g/L [28]. Taking into account that serum contains 10% of
lood Mn  (e.g., Baker et al. [26]) the serum concentration in those
amples would be again ca. 0.4–1.8 g/L, with a mean at 0.9 g/L.
his is covering the majority of values reported for the samples in
his paper. This shows that Mn  is strictly regulated but long-term,
utritional, environmental or occupational exposure can results
n rather stable, but somewhat elevated values compared to non-
xposed persons.
However, independent on their origin for all samples it was
hown that at low total Mn  concentration in serum (Mn(S)) a
hange in major Mn  carriers in serum took place from Mn-
ransferrin (Mn-Tf(S)) toward Mn-citrate (Mn-Cit(S)) with high
tatistical signiﬁcance.
This carrier switch from Mn-Tf(S) to Mn-Cit(S) was observed
etween Mn(S) concentrations of 1.5 g/L to ca. 1.7 g/L. For the SEC column (separation range <2000 Da). Most of Mn is co-eluting with a citrate
luting (modiﬁed from [19] with permission from Royal Society of Chemistry).
Munich sample donors both, serum and cerebrospinal ﬂuid were
available. For these samples additionally the concentration of Mn  in
cerebrospinal ﬂuid (Mn(C)) positively correlated to MnCit(S) when
Mn(S) concentration was above 1.7 g/L. (Fig. 3).
It should be taken into mind that the ﬁndings regarding the
switch of the Mn-carrier in serum samples were related to serum
samples from different regions, i.e. from Munich (n = 39), the
Emilia Romagna region in Italy (n = 52) and from Sweden (n = 89).
This change in Mn-carrier was  observed in each of these sam-
ple subsets but nevertheless regional differences were elucidated
by application of a multiple regression model. With respect to
the same level of total Mn(S), in average the level of Mn-Cit(S)
was lower by −0.921 g/L in Emilia-Romagna-Region compared
to Munich, whereas in Sweden it was higher by 0.289 g/L com-
pared to Munich. These differences were partly signiﬁcant: The
variables “Emilia Romagna Region” and “Munich” were signiﬁcant
contributions to the multiple regression model (p = 4.8 × 10−120
and p = 0.000649, respectively), whereas the variable “Sweden”
appeared to be not signiﬁcant: p < 0.145). As no paired samples
were available from Italy or Sweden, it was not possible to study
the consequences of these regional/occupational differences on
Mn(C). Switch points from Mn-Tf(S) to Mn-Cit(S) were calculated
for each subset additionally and were found at Mn(S) concentra-
tions of 1.31 g/L (Swedish samples), 1.26 g/L (Munich samples)
and 2.14 g/L (Emilia Romagna samples). The reason for the higher
value of the switch point for the “Emilia Romagna” samples is still
unclear [29].
Iron and manganese are known as competitors for binding sites,
e.g., at transferrin or citrate [15,30]. Therefore, measurements of
total Fe in serum (Fe(S)), Fe-transferrin in serum (Fe-Tf(S)) and
Fe-citrate in serum (Fe-Cit(S)) were included in this study. These
measurements showed that the Fe-species had the same mean
values for serum samples, irrespective of the Mn  serum concen-
trations. No correlation between Mn(S) and Fe(S) or Fe-species was
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sig. 3. Correlation of Mn-Tf(S) and Mn-Cit(S) versus Mn(S) are plotted. The zoom
witch  can be observed. The arrows mark the switch points at 1.51 g/L, calculated
rom  [29], with permission from Elsevier.
etected. The explanation was given by the thousand fold Fe con-
entration compared to Mn  concentration and the Fe/transferrin
aturation rate being only at 25–30% [31,32], which means that
pproximately 70% of the binding sites are still available for Mn
inding. As an example, Aschner quantiﬁed the available binding
ites for Mn as 50 M,  corresponding to 2750 g Mn/L [15]. Thus,
n displacement from transferrin to citrate by iron seems not likely
nd the independency of Fe from Mn  concentration in our serum
amples was in line with this unlikeliness.
So far the reason why Mn  switches from Tf(S) to citrate(S) is
ot explained. May  be it is related to the similar switch for iron
rom Fe-Tf(S) to Fe-Cit(S) [33]. This reference gives a comparative
verview about the non-transferrin-bound iron. Nevertheless the
uthors state that the source of plasma non-transferrin-iron is not
ully understood. It remains to be clariﬁed whether it appears after
ellular iron deﬂuxion or whether it is following the equilibrium
etween transferrin-iron and the potential carriers (mainly citrate).
.2. Mn-Transporters across NB discussed in literature
It should be underlined that the positive correlation between
n-Cit(S) and Mn(C) does not justify yet the conclusion of a facil-
tated Mn  transport through NB by means of Mn-citrate. Actually,
he exact mechanism of Mn  uptake across the NB into brain has not
een investigated within the Mn-speciation project of our group.
t is still under debate in literature and has to be revealed: An
n vitro study in a porcine model compared the effect of MnCl2
n blood-cerebrospinal ﬂuid barrier (BCB) and blood-brain barrier
BBB) where Mn  affected the BCB more than the BBB [34]. Bornhorst
t al. [34] concluded that the passage across BCB into the brain is
he preferred route for Mn  over BBB. Whether this conclusion may
e transferred also to mechanisms of in vivo Mn intake in humans
resently remains to be shown.
In general it is accepted that Mn  can cross the neural barriers
NB) by means of transporters and in different oxidation states,
ince the Mn  absorption, transport, and tissue levels are stringentlydow shows the Mn(S) concentration range below 2.4 g/L where the Mn-carrier
Mn-Tf(S) intercepts, or at 1.66 g/L, calculated from Mn-Cit(S) intercepts. Modiﬁed
regulated [35]. Although Mn  transporter systems across the NB
have been vigorously investigated, a probative result is presently
not available [35,36]. Referring to references [37,38] Aschner et al.
[6] favour transferrin receptor (TfR) and divalent-metal transporter
1 (DMT-1) for Mn  transporters across NB whereas Yokel [8] ranked
the role of DMT-1 as questionable. He assessed the evidence to be
stringently against a role of DMT-1 in Mn  transport, but found no
direct evidence for its role. Yokels appraisal is close to Refs. [3],
[34] and [39] who accordingly report DMT1 to be not the major
transporter for Mn  uptake into the brain via the NB.
Apart from the controversially debated DMT-1, several more
transporter systems were investigated and are summarized in [40].
In connection with our ﬁndings of a switch of Mn-carriers from
transferrin to citrate at elevated Mn  concentration the paper from
Bowman is of interest: They implied a citrate transporter across
NB [35] with a Mn-citrate tridentate complex (Mn-CTC) having
a non-coordinated central carboxylate recognition moiety. They
hypothesized, that the Mn-CTC might be a substrate for the organic
anion transporter or a monocarboxylate transporter (MCT). Various
cellular processes could regulate the activity of the above men-
tioned transporters in response to Mn  deﬁciency or overload.
3.3. Mn-speciation in animal studies
Although, the debate about Mn  transporters across NB is not
ﬁnished yet, it is clear from various studies in humans including MRI
and from animal studies that manganese enters the brain. There it
is able to deploy its detrimental neurotoxic potential.
That fact necessitated the implementation of further animal
studies for additional information about Mn-species formation
within a complete biological system (=organism) and related
metabolic changes in brain.As summarized by Gwiazda et al. [41] previous animal stud-
ies may  be considered as inappropriate with respect to chosen
exposure concentrations, which considerably exceeded the doses
where neurological symptoms appeared in occupationally exposed
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umans (10–15 mg/kg b.w., cumulative). Such studies were inap-
licable for risk assessment of chronically, low-level Mn  exposure
or humans. Therefore, our experimental set-up was oriented on
oncentrations relevant for single-low-dose occupational exposure
r for exposure by diffuse sources like environmental pollution (as
uggested by Lucchini and Zimmermann [42]).
In a ﬁrst trial Diederich et al. [43] exposed rats by a single i.v. Mn-
njection (1 mg/kg b.w., Mn-species: inorganic MnCl2) and mon-
tored Mn-speciation in serum one hour after exposure (serum
1h”) and after sacriﬁce of animals four days later (serum “4d”)
ogether with brain extracts (brain “4d”). This four-days period
orresponded to Takeda et al. [44] who reported maximum Mn
istribution from serum to brain after 4 days.
Serum “1h” showed a 100-fold total Mn  concentration increase,
he major Mn-species still being the injected inorganic Mn,  while
n-Tf exhibited ca. 33 fold and Mn-Cit ca. 4–5 fold increase, each
ompared to controls. In serum “4d” Mn  species were nearly plan-
shed again with Mn-Tf and Mn-Cit both having less than 1.3 fold
ncrease (vs. controls) [43]. This supported the fast turnover of Mn
escribed in literature [3].
In brain “4d”, however, Mn-quantitation (as g Mn/g brain “4d”)
howed LMM-Mn  species to be the absolute dominating Mn  com-
ounds with inorganic Mn  to be the major Mn  species, followed by a
onsiderable increase of Mn—citrate. Interestingly, the level of Mn-
f in brain “4d” (behind NB) was increased only 1.1 fold, remained
early as low as in controls, although in serum “1h” (before NB) it
ad been signiﬁcantly increased compared to controls. Summariz-
ng Diederichı´s ﬁndings we concluded that i.v. injected inorganic
n  complexed quickly with physiological Mn-carriers like Mn-Tf
n serum, but for distribution across NB into brain LMM-Mn-species
ere the more important carriers. These results conﬁrmed our pre-
ious ﬁndings on Mn  distribution and our conclusions from human
erum and CSF samples. They were also in accordance with others
ho suggested a LMM Mn-carrier to brain, which was  independent
rom transferrin and Tf-R [24,45–47].
The starting animal study conducted by Diederich et al. [43]
id not include metabolomics aspects. For a complete simula-
ion of single-low-dose occupational exposure including both,
etabolomics investigation and Mn-speciation, we  repeated this
njection study and furthermore compared it with a simulation of
ong-term-low dose (environmental) exposure by application of a
3 days lasting sub-chronic, low-dose feeding (500 mg  Mn/kg feed)
f rats followed from Mn-speciation and metabolomics studies in
rain [48,49].
Samples from both exposure scenarios were analyzed for total
n in serum and brain, Mn  species as well as Fe(II)/(III) in brain
xtracts. Besides, glutamate, acetylcholinesterase, oxidative stress-
nd inﬂammation markers were measured and non-targeted
etabolomics was performed [48–50].
Total Mn was increased in serum “1h” from 7 ± 2 g/L to
94 ± 49 g/L (p < 0.001), however, four days later, in serum “4d”
he concentration was re-balanced and practically the same as in
ontrols (controls: 6.0 ± 1.5 g/L, exposed: 6.7 ± 1.3 g/L). This is
ccording with serum from the feeding trial where the concentra-
ions were about the same as in controls (controls: 4.5 ± 0.8 g/L,
xposed: 4.7 ± 0.7 g/L) [48,51]. This unchanged Mn-concentration
n serum after long-term-low-dose Mn-exposure was surprising
hen looking just on serum but might be explained by distribution
o organs in parallel as monitored by the Mn  increase e.g., in brain
see below: +19%; and supposedly increased in kidney or liver, as
etected in another experiment by Diederich et al. [43]).
In Mn-exposed groups of both exposure conditions the concen-
rations of HMM  compounds were lower and LMM  Mn-species
uch as Mn-citrate or Mn-amino acids higher than in controls.
nterestingly, this increase of LMM  Mn-species was  even strongest
fter the sub-chronic Mn  feeding. In contrast, four days after Mnedicine and Biology 37 (2016) 50–61
injection, these LMM  fractions were only about 2-fold increased
whereas one hour after injection Mn  was still present predom-
inantly as inorganic Mn.  Summarizing the above results, we
concluded that a short Mn  exposure already started the formation
of LMM  Mn-species within serum. This formation rapidly devel-
oped under longer exposure time, as imitated by the feeding study.
From our previous studies we  learnt that there is an enhanced inﬂux
speciﬁcally of Mn-LMM-species across NB to brain [21,43] which
was found by elevated Mn  values in brain, too. This “drain” from
serum to other organs, i.e., brain, explains the unchanged serum
Mn values.
After Mn  exposure, total Fe in serum was decreased, signiﬁcantly
by 80% in the feeding trial but only 16% after injection [51]. These
effects seem not to be in line with the ﬁndings from humans, where
no correlations between Mn  and Fe concentrations were seen (see
above). A ﬁnal explanation is not at hand, yet, but, on the one hand,
there might be differences in the physiological behavior between
rats and humans. On the other hand an explanation could be that
the unchanged Mn  serum concentrations after the feeding exper-
iment result from an efﬁcient transport from serum into organ
(including brain) which appears parallel to the continuous, daily
exposure by feed. This had been observed previously by Diederich
et al. [43] and in Neth’s paper [48] it is seen by an increase of Mn  in
brain. The question why  iron is changed by −80% in the feeding trial,
while no changes were seen in humans could be explained by the
fact, that the overall Mn-mass exposed to rats during seven weeks
feeding is much higher than Mn  being typically present in unex-
posed humans. Changes in Fe concentration supposedly appear
only when at least a certain Mn-exposure has been exceeded. This
explanation seems to be supported by the much smaller reduction
of Fe concentration after the injection experiment.
In brain total Mn  was  increased by around 19% to ca. 429 ± 17 g
Mn/kg in both trials, whereas Fe concentrations decreased in the
feeding trial 1.44 fold down to 9 g Fe/kg or remained practically
constant at 13 g/kg after injection.
Mn-speciation in brain extracts of the feeding trial showed
LMM-Mn-carriers to be the major Mn-compounds with 38%
increase compared to controls. This increase was  accompanied
by a remarkable decrease in HMM-Mn  molecules by 57%. Aside
from Mn-citrate and Mn-amino acids, inorganic Mn  was  present in
higher amounts than in control samples (∼32%). Four days after
the i.v. injection of MnCl2, LMM  Mn-species were increased in
exposed rats in similar manner as in the feeding study by 27%. The
percentaged amount of Mn  bound to HMM  or inorganic Mn  was
comparable between control and exposed animals.
In summary, the ﬁndings from these animal studies can be seen
as concordant with respect to formation of LMM  Mn-species during
the applied exposure conditions. Dependent on the kind of expo-
sure the preferential formation of Mn-citrate or Mn-amino acids
in serum turned out to be stronger for example in the case of a
subchronic, low-dose increased feeding of Mn.  These LMM-species
might then be involved in the transport of Mn across NB, what was
substantiated by the Mn-speciation in brain extracts. One major
prerequisite for this is that control mechanisms, such as it is the
case for transport via the Tf-receptor, might not be facilitated any
more under exposure situations.
3.4. Mn  exposure and mechanisms of detrimental effects
In brain, parallel to changes of Mn-species also changes of total
iron and Fe-species were observed related to Mn-exposure scenar-
ios.It is known that Fe deﬁciency can enhance Mn  accumulation
while Mn  treatment can likewise alter Fe homeostasis [52–55].
Despite the knowledge of altered Fe concentrations in the brain
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xidation state of Fe during such conditions. Therefore, within our
roject Fernsebner et al. [50] developed a method for measuring
e(II) and Fe(III) within the animal studies of subchronic and acute
n  exposure.
Regarding the sufﬁciently high Fe concentrations in brain
xtracts and the non-interferred iron elemental lines, Fe was  deter-
ined by ICP-OES without complications. For separation of the two
e species, ion chromatography (IC) was applied.
The most important ﬁnding of the analysis of brain extracts was
 shift from Fe (III) toward Fe(II) by a factor of around 2.5 in the
amples from the subchronic feeding of Mn  in rats when com-
ared to controls. This clear shift was not observed after the single
.v. injection of MnCl2 in rats, suggesting that longer incubation
imes of Mn  are required for such changes in the neural Fe(II)/(III)
atio. Fe(II) was positively correlated with Mn  concentrations in the
rain extracts. This positive correlation was even more pronounced
nder subchronic Mn-exposure.
It is generally accepted that free Fe(II) is oxidized to Fe(III) by
uperoxide dismutase (SOD) or glutathione peroxidases (GPx) lead-
ng to neutralization of this toxic Fe species [56]. Since Mn  might
nhibit anti-oxidative enzymes such as SOD, this neutralization may
ot be maintained, leading to an accumulation of Fe(II) as observed
n the feeding study [57]. By reaction of Fe(II) with H2O2 via the
enton reaction, reactive oxygen species (ROS) are formed, which
an contribute to inﬂammation or destruction of neural tissue. Con-
luding, Mn  low level long term exposure (feeding) shifted Fe(III)
oward Fe(II), i.e. by this means toward generation of oxidative
tress in brain.
The hints about ROS generation were further veriﬁed by the
ubsequent metabolomics studies using ESI-FT-ICR-MS, speciﬁcally
n the feeding trial. In brain extracts, the oxidative stress marker
lutathione-disulﬁde (GSSG, oxidized glutathione (GSH)) was
ncreased about two-fold, inﬂammation markers prostaglandine B1
PGB1) or prostaglandine H2 (PGH2) were increased two or six-fold
nd the marker for lipid peroxidation 15-hydroxyeicosaeonic acid
15(S)-HETE) was elevated even 28-fold [50].
The Mn-caused disturbance in oxidative defence mechanisms,
hown by the increase of the oxidized form of glutathione, is
elevant for understanding brain damage mechanisms. Genera-
ion of ROS and—as a consequence—the unbalanced anti-oxidative
efence system has been reported for several neurological disor-
ers. During PD progression an increased GSSG/GSH ratio indicates
xidative stress [58]. The observed shift toward GSSG was fur-
her supported by the reduction of the GSH precursor molecule
-glutamylcysteine, indicating that the synthesis of GSH seemed
o be interfered at an early stage. Interestingly, ophthalmic acid
as elevated in the brain of Mn-treated rats. This GSH analogous
eptide is considered as biomarker of oxidative stress [59].
Our ﬁnding of increased lipid peroxidation, demonstrated by
he increase of 15 (S)-HETE or ResolvinD2, has parallels in liter-
ture, too: Kapich et al. observed an effective lipid peroxidation
f fungal manganese peroxidase on C18 unsaturated fatty acids
60]. Furthermore, the pool of the major poly-unsaturated fatty
cids docosahexanoic acid (DHA) and arachidonic acid appeared
epleted whereas their lipid mediators PGB1, 15(S)-HETE and
esolvinD2 were found to be increased after Mn  injection. This
oints to an activation of inﬂammatory response using cyclo-
xygenase (COX)- or lipoxygenase (LOX)—pathways [61], where
he latter was found to be involved also in other neurodegenerative
iseases such as Alzheimer’s Disease [62].
To complete our puzzle, it was further of interest whether
eurotransmitters were inﬂuenced in our exposure trials. The
nﬂuence of Mn  on glutamate and gamma-aminobutyric acid
GABA) is known from literature [63]. In this review the sum-
arized data were still conﬂicting, but it was beyond question,
hat the GABAergic systems of the basal ganglia were affectededicine and Biology 37 (2016) 50–61 57
and excitatory neurotransmitters such as glutamate or inhibitory
neurotransmitters like GABA or the activity of acetylcholinesterase
(AchE) were shown to be affected in Mn-induced neuroinﬂamma-
tion [63,64]. Based on these reports we measured glutamate and
acetylcholinesterase activity in brain extracts. Glutamate showed
no change in the brain “4d” extracts after Mn  injection but its
concentration was signiﬁcantly elevated (+16%, p < 0.05) in brain
extracts from the feeding trial. There we  observed actually a clear
positive correlation between Mn  and glutamate concentration.
Other than glutamate, AchE activity was affected in both trials, i.e.
increased by 9% (p < 0.05) in brain extracts of the feeding trial and
by 15% (p < 0.05) in brain “4d” extracts of the injection trial. This dif-
ference might be explained by previous reports where AchE activity
rapidly increases after short term exposure [65] but decreases dur-
ing long term (e.g., 1–2 years) exposure [66,67]. While four days is
considered to be still a short period, seven weeks may be already
in an early stage of the declining period from an initial increase to
the decrease after several months.
Both, the increase of glutamate concentration as well as the
increase of AchE activity in brain are accompanied by changes of
neuronal excitability in basal ganglia and are linked to neurodegen-
erative diseases like amyotrophic lateral sclerosis, Alzheimerı´s and
Parkinson disease [68–70]. Thus, with the above ﬁndings a molecu-
lar mechanism how Mn  exposure leads to symptoms similar to PD
was observed.
Finally non-targeted metabolomics studies completed our puz-
zle so far.
ESI-FT-ICR-MS analysis was applied in methanolic brain
extracts. In sum, 9865 masses were detected in all extracts, of which
ca. 13.5% could be annotated by MassTRIX webserver [71] and thus
were regarded as “known” metabolites. Statistical analysis with
OPLS-DA of the entire dataset revealed a good separation between
the control and Mn-treated group.
“Known” metabolites were subsequently analyzed by “KEGG
color pathway database” [72] to ﬁnd changes in involved metabolic
pathways. Major changes could be observed for purine and pyrimi-
dine metabolism, amino acid metabolism, glucose, and glutathione
metabolism as well as for biosynthesis of fatty acids.
Purine nucleosides are involved in a variety of intracellular neu-
ronal processes and provide precursors of RNA and DNA  [73]. In
our studies nearly all detected purines or pyrimidines were signiﬁ-
cantly decreased in rat brain extracts after Mn  exposure, except for
hypoxanthine, AMP  (adenosine monophosphate), GMP  (guanosine
monophosphate) and GDP (guanosine diphosphate)-3,6-dideoxy-
galactose. Their concentration changes are mediated by adenosine
receptors which can complex with dopamine receptors, enabling
purines to ﬁne-tune neurotransmission in basal ganglia [74,75].
This includes inverse regulation of glutamate, serotonin and acetyl-
choline excretion [74,76–78]. In short terms: The more purines are
interacting with adenosine receptors, the less neurotransmitters
mentioned are excreted.
Another interesting ﬁnding of OPLS data analysis revealed that
Mn-species in brain extracts correlated group-wise with pyridines
or pyrimidines: LMM-Mn  species, including Mn-citrate, correlated
exclusively positive with AMP, UDP, UMP, GMP  but mostly nega-
tive with all the other metabolites, whereas Mn-proteins showed
inverse correlation (negative to AMP, UDP, UMP, GMP, but positive
to all others; except for one protein fraction which correlated only
negative to all compounds). (Fig. 4).
For perfecting our Mn-speciation project we investigated the
spatial distribution of Mn,  Fe, Zn and Cu in frozen microtome slices
of rat brains (Mn-exposed vs. controls) using laser ablation-ICP-MS.
For quantiﬁcation (wet-) frozen layers of spiked brain homogenates
were employed [51] resulting in values given in [g (element)/g
wet brain mass]. Fig. 5 shows photographs of the brain slices
(exposed/control) in the ablation chamber snapshotted by the inte-
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Fig. 4. Heatmap of the OPLS data analysis of the purin/pyrimidin analysis and its interrelation to Mn-species: LMM-Mn species positively correlate with UMP, UDP, AMP
and  GMP  and correlate mainly negative with all other compounds. In contrast, Mn-proteins positively correlate with all other but negatively with UMP, UDP, AMP and GMP.













under Mn  exposure HMM-Mn  species did not increase in serum or
were even lowered, in contrast to LMM-Mn  species, e.g., Mn-citrate,
which were increased. A Mn-citrate complex could be identiﬁed by
2-D approaches including ESI-FT-ICR-MS. It was further seen,thatrated camera and the elemental maps of the brains scanned by
A-ICP-MS. Most notably, the Mn-map of the exposed brain shows
ellow color areas with even red spots in the basal ganglia, indi-
ating high Mn  concentration. This is opposite to the same brain
egion of the control rat showing mainly green color (low Mn
oncentration). The same brain regions show even more elevated
oncentration for zinc, as indicated by the red color, whereas iron
ecreased considerably compared to controls, shown by blue color
or respective brain regions. The well known competition of Mn
nd Fe explains the invers situation in basal ganglia for both ele-
ents. The ﬁndings also conﬁrm the above reported results aboutotal element concentrations in brain.4. Summary
The manganese speciation project in our laboratory was aimed
ﬁrst to clarify in which chemical form Mn  is reaching neural bar-
riers. Therefore, Mn-speciation in serum (before NB) and in CSF
(behind NB), notably in paired serum and CSF samples was  investi-
gated. Most important ﬁndings from these experiments were that
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leen,  scanned by LA-ICP-MS. The asterisks in the concentration-color code bare on 
espective elements determined in rat brain. For manganese, the black asterisk indi
rom  [51], with permission.
n-citrate was enriched up to ﬁve-fold across NB. This was con-
radictory to all other Mn-species investigated. We  showed with
n increased sample size that at slightly elevated total Mn(S) con-
entration a change in Mn  carriers toward Mn-citrate takes place.
arallel to this carrier change, for an especially studied subset
e have shown that Mn  beyond the neural barrier, i.e., Mn(C),
orrelates to this second carrier Mn-citrate(S) at higher Mn(S) con-
entration, reﬂecting the facilitated transport of Mn  into the brain.
he latter has been conﬁrmed also in rat brain after single low dose
xposure [43] and also after low-dose 7 weeks feeding. Comparing
hort term vs. long term exposure (both low levelled) we  found
hat the short Mn  exposure already started the formation of LMM
n-species within serum. This formation rapidly developed under
onger exposure time, as imitated by the feeding study. Therefore,ht side shows the (wet-) concentration determined for the bulk concentrations of
the bulk concentration for control animals, the blue one for exposed rats. Modiﬁed
Mn-Citrate appears to be that important Mn  metabolite reaching
the brain after Mn  exposure.
The second aim of the manganese project considers the clar-
iﬁcation of the mechanism of neuronal damage, caused by Mn.
Therefore, iron, being a competitor to Mn,  was investigated.
Mn  exposure altered the Fe metabolism in brain. The total Fe
concentration was reduced and the important homeostasis of the
Fe(III)/Fe(II) ratio was disturbed by a shift from Fe(III) to Fe(II)
observed after a low dose (long-term) exposure. This shift indicated
a severe metabolic change toward oxidative stress in brain. This
ﬁnding was supported by results from our metabolomics studies:
Oxidative stress- and inﬂammation markers as well as lipid per-
oxidation markers were signiﬁcantly elevated after Mn  exposure.
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dditionally, many metabolic pathways (of which several have to
e still identiﬁed) were severely altered.
Finally, changes in the GABAergic system were monitored with
igniﬁcant elevation of glutamate concentration (only in feeding
rial) and AchE activity (in both trials). Both effects cause changes
f neuronal excitability in basal ganglia. This relationship between
euronal excitability and increase of AchE or glutamate explains
he similarity of Mn-dependent symptoms to Parkinson disease.
lthough, many pieces of this puzzle were clariﬁed, a couple of
uestions remain open so far, such as probably a deﬁnitive answer
n the Mn-transported across NB or the balance/imbalance of metal
pecies ratios of different metals like Zn-Cu-Mn-Fe which might
nteract in a network.
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